{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:09:05Z","timestamp":1792638545381,"version":"4.5.0"},"reference-count":61,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Med Oncol"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:p>Datopotamab deruxtecan (Dato-DXd) is a novel antibody-drug conjugate currently under investigation in clinical trials of various solid tumors. In this manuscript, an international steering committee formed by medical oncologists, ophthalmologists, and pulmonologists reached consensus to provide multidisciplinary healthcare professionals (HCPs) with practical recommendations for Dato-DXd adverse event (AE) prevention, monitoring, and management in patients with advanced\/metastatic non-small cell lung cancer. Experts\u2019 recommendations focused on the following AEs: oral mucositis\/stomatitis, interstitial lung disease\/pneumonitis, ocular surface events, nausea, and vomiting. Based on available guidelines, clinical trials data, and real-world experience, 55 statements were developed and, as per Delphi methodology, all reached consensus with more than 75% of experts\u2019 agreement. The key recommendations include preventive measures, such as proactive communication between patients and caretakers, regular clinical examinations, collaboration with multidisciplinary HCPs; and monitoring measures, such as treatment dosage and care planning decisions based on the level of severity of each AE. Experts pointed out real-world challenges and local differences on AEs management and gave insight into implementation of regional strategies with a multidisciplinary collaboration approach. Dato-DXd AEs awareness, understanding, and proper management via a well-established multidisciplinary collaboration is crucial to guarantee patients\u2019 quality of life. This international consensus aims to provide comprehensive recommendations for Dato-DXd AEs management, considering the regional and institutional differences present in the healthcare system, such as access to examinations and treatment possibilities.<\/jats:p>","DOI":"10.1177\/17588359261469539","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T06:36:10Z","timestamp":1785825370000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Consensus recommendations for the management of Dato-DXd-associated adverse events in patients with advanced\/metastatic NSCLC: insights from a multiregional steering committee"],"prefix":"10.1177","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5008-8854","authenticated-orcid":false,"suffix":"Jr","given":"William Nassib","family":"William","sequence":"first","affiliation":[{"name":"Grupo Oncoclinicas, Sao Paulo 01309-000, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8154-6966","authenticated-orcid":false,"given":"Daniel","family":"Brungs","sequence":"additional","affiliation":[{"name":"Graduate School of Medicine, University of Wollongong, Wollongong, NSW, Australia"},{"name":"Southern Medical Day Care Centre, Wollongong, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emerson","family":"Fernandes de Sousa e Castro","sequence":"additional","affiliation":[{"name":"Clinica Visao, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6607-1106","authenticated-orcid":false,"given":"Herbert H.","family":"Loong","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, State Key Laboratory in Translational Oncology (CUHK), The Chinese University of Hong Kong, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James C. H.","family":"Yang","sequence":"additional","affiliation":[{"name":"National Taiwan University College of Medicine, Taipei, Taiwan"},{"name":"National Taiwan University Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-Ah","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet ali Nahit","family":"Sendur","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Ankara Yildirim Beyazit University, Ankara, Turkey"},{"name":"Department of Medical Oncology, Ankara Bilkent City Hospital, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Mokhtar","sequence":"additional","affiliation":[{"name":"Department of Oncology, Kasr Al-Ainy School of Medicine, Cairo University, Cairo, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se-Hoon","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Hematology\u2013Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senthil","family":"Rajappa","sequence":"additional","affiliation":[{"name":"Basavatarakam Indo American Cancer Hospital and Research Institute, Hyderabad, Telangana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3520-9464","authenticated-orcid":false,"given":"Stephanie P. L.","family":"Saw","sequence":"additional","affiliation":[{"name":"National Cancer Centre Singapore, Singapore City, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0198-1077","authenticated-orcid":false,"given":"Tsung-Ying","family":"Yang","sequence":"additional","affiliation":[{"name":"Taichung Veterans General Hospital, Taichung, Taiwan"},{"name":"National Chung Hsing University, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6089-1840","authenticated-orcid":false,"given":"Tuncay","family":"G\u00f6ksel","sequence":"additional","affiliation":[{"name":"School of Medicine and Translational Pulmonary Research Center (EgeSAM), Ege University, Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"key":"e_1_3_4_2_2","first-page":"2013","volume-title":"Lung cancer","author":"World Health Organization","unstructured":"World Health Organization. Lung cancer. World Health Organization 2026, 2013\u20132014."},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-025-01679-1"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2023.2198087"},{"key":"e_1_3_4_5_2","first-page":"1","article-title":"Clinical applications of antibody-drug conjugates in advanced non-small cell lung cancer","volume":"17","author":"Guo H","year":"2026","unstructured":"Guo H, Xu Z, Li K, et al. Clinical applications of antibody-drug conjugates in advanced non-small cell lung cancer. Front Immunol 2026; 17: 1\u201318.","journal-title":"Front Immunol"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S466220"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-21-0206"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00059"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.2348"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01909"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-01349"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2024.2409621"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2023-0230"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2023.09.043"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2025.43.16_suppl.8501"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-01544"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2023-0228"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1177\/17588359241248336"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00920"},{"key":"e_1_3_4_20_2","first-page":"19","article-title":"FDA approves datopotamab deruxtecan-dlnk for unresectable or metastatic HR-positive, HER2-negative breast cancer","author":"U.S. Food and Drug Administration","year":"2025","unstructured":"U.S. Food and Drug Administration. FDA approves datopotamab deruxtecan-dlnk for unresectable or metastatic HR-positive, HER2-negative breast cancer. FDA 2025; 19\u201320.","journal-title":"FDA"},{"key":"e_1_3_4_21_2","first-page":"5","article-title":"FDA grants accelerated approval to datopotamab deruxtecan for EGFR-mutated non-small cell lung cancer","volume":"05","author":"US Food and Drug Administration","year":"2025","unstructured":"US Food and Drug Administration. FDA grants accelerated approval to datopotamab deruxtecan for EGFR-mutated non-small cell lung cancer. FDA 2025; 05: 5\u20137.","journal-title":"FDA"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf225"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102720"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103479"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.556"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.776"},{"issue":"3","key":"e_1_3_4_27_2","article-title":"Prophylaxis, clinical management, and monitoring of datopotamab deruxtecan-associated oral mucositis\/stomatitis","volume":"30","author":"Meric-Bernstam F","year":"2025","unstructured":"Meric-Bernstam F, Bardia A, Bossi P, et al. Prophylaxis, clinical management, and monitoring of datopotamab deruxtecan-associated oral mucositis\/stomatitis. Oncologist 2025; 30(3): oyaf031.","journal-title":"Oncologist"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.102638"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.13058"},{"key":"e_1_3_4_30_2","article-title":"LBA12 Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced\/metastatic (adv\/met) non-small cell lung cancer (NSCLC): results of the randomized phase III study TROPION-Lung01","volume":"34","author":"Ahn M-J","year":"2023","unstructured":"Ahn M-J, Lisberg A, Paz-Ares L, et al. LBA12 Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced\/metastatic (adv\/met) non-small cell lung cancer (NSCLC): results of the randomized phase III study TROPION-Lung01. Ann Oncol 2023; 34: S1305\u2013S1306.","journal-title":"Ann Oncol"},{"key":"e_1_3_4_31_2","article-title":"552P TROPION-Lung05: datopotamab deruxtecan (Dato-DXd) in Asian patients (pts) with previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)","volume":"34","author":"Ahn M-J","year":"2023","unstructured":"Ahn M-J, Cho BC, Goto Y, et al. 552P TROPION-Lung05: datopotamab deruxtecan (Dato-DXd) in Asian patients (pts) with previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs). Ann Oncol 2023; 34: S1684\u2013S1685.","journal-title":"Ann Oncol"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.8623"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-024-02738-3"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2023.05.010"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-020-01715-7"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21704"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13020268"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12903-025-05579-1"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.25122\/jml-2023-0041"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2015.0064"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.3389\/ftox.2023.1137637"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2017.05.001"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0057"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.e15001"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx225"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/123876"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1186\/2213-0802-2-4"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2022.2162383"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm7100356"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02776-2021"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.2174\/1874306401206010063"},{"key":"e_1_3_4_52_2","first-page":"3","article-title":"Nivolumab for NSCLC in Japanese patients: similar benefits, but beware of pneumonitis","volume":"1","author":"Vansteenkiste J.","year":"2016","unstructured":"Vansteenkiste J. Nivolumab for NSCLC in Japanese patients: similar benefits, but beware of pneumonitis. ESMO Open 2016; 1: 3\u20135.","journal-title":"ESMO Open"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13087"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.1111\/resp.14766"},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12282-025-01670-1"},{"key":"e_1_3_4_56_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01296"},{"key":"e_1_3_4_57_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw270"},{"key":"e_1_3_4_58_2","unstructured":"National Comprehensive Cancer Network. Antiemesis. NCCN Guidelines Version 2."},{"key":"e_1_3_4_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.102195"},{"key":"e_1_3_4_60_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv202"},{"key":"e_1_3_4_61_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33100"},{"key":"e_1_3_4_62_2","unstructured":"U.S. Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE) version 5.0 https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events\/ctcae-v5-5x7.pdf (2017 accessed 16 December 2025)."}],"container-title":["Therapeutic Advances in Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359261469539","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17588359261469539","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359261469539","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T13:18:51Z","timestamp":1786022331000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17588359261469539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":61,"alternative-id":["10.1177\/17588359261469539"],"URL":"https:\/\/doi.org\/10.1177\/17588359261469539","relation":{},"ISSN":["1758-8359","1758-8359"],"issn-type":[{"value":"1758-8359","type":"print"},{"value":"1758-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]},"article-number":"17588359261469539"}}